Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ) earnings
JAZZ earnings moved a median of +1.09% by the close. Quarterly and annual JAZZ reports and results, each read against the price at its own news timestamp. Back to the JAZZ overview →
27 measured JAZZ earnings events.
Where these JAZZ earnings landedvs 27 measured JAZZ earnings reactions
| Middle 50% of JAZZ earnings reactions | -3.67% to +2.44% |
|---|---|
| Median reaction (to close) | +1.09% |
| Measured reactions | 27 |
Point-in-time · zero look-ahead
Half of the 27 JAZZ earnings events with a measured close landed between -3.67% and +2.44%; 56% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Jazz Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | -1.78% | +2.44% | |
| Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results | Press release | -1.78% | +2.44% | |
| Form 10-Q Jazz Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | -0.46% | -0.04% | |
| Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results | Press release | -0.46% | -0.04% | |
| Form 10-K/A Jazz Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +0.08% | +1.54% | |
| Form 10-K Jazz Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +0.07% | +9.35% | |
| Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance | Press release | +0.07% | +9.35% | |
| Form 10-Q Jazz Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | -3.47% | -6.25% | |
| Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance | Press release | -3.47% | -6.25% | |
| Form 10-Q Jazz Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +1.53% | -1.51% | |
| Jazz Pharmaceuticals Announces Second Quarter 2025 Financial Results and Updates 2025 Financial Guidance | Press release | +1.53% | -1.51% | |
| Form 10-Q Jazz Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | +2.62% | -3.67% | |
| Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance | Press release | +2.62% | -3.67% | |
| Form 10-K/A Jazz Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +0.62% | +1.50% | |
| Form 10-K Jazz Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | -2.05% | +3.33% | |
| Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2024 Financial Results and Provides 2025 Financial Guidance | Press release | -2.05% | +3.33% | |
| Form 10-Q Jazz Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | -0.20% | +1.47% | |
| Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results | Press release | -0.20% | +1.47% | |
| Form 10-Q Jazz Pharmaceuticals For: Jun 30 | SEC filing · Form 10-Q | +1.55% | +1.09% | |
| Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance | Press release | +1.55% | +1.09% | |
| Form 10-Q Jazz Pharmaceuticals For: Mar 31 | SEC filing · Form 10-Q | +0.29% | +3.95% | |
| Jazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance | Press release | +0.29% | +3.95% | |
| Form 10-K/A Jazz Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | +0.25% | +1.20% | |
| Form 10-K Jazz Pharmaceuticals For: Dec 31 | SEC filing · Form 10-K | -3.19% | -5.26% | |
| Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance | Press release | -3.19% | -5.26% | |
| Form 10-Q Jazz Pharmaceuticals For: Sep 30 | SEC filing · Form 10-Q | -1.03% | -9.32% | |
| Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance | Press release | -1.03% | -9.32% |
Keep exploring
More JAZZ: analyst actions → · SEC filings → · JAZZ overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ANTHERA PHARMS INC NEW (ANTH) | 546 | -0.01% | 40% |
| GENEREX BIOTECHNOLOGY (GNBT) | 546 | 0.00% | 49% |
| FLEX PHARMA (FLKS) | 541 | -0.16% | 43% |
| OSIRIS THERAPEUTICS (OSIR) | 538 | 0.00% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.